CXCR1 and CXCR2-modified CD70-specific CAR T cells have been demonstrated to improve T cell trafficking and antitumor efficacy via IL-8-mediated chemotaxis in an in vivo glioblastoma model [147]. The gene discussed is CD70; the disease is glioblastoma.